SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

09 Nov 2023 Evaluate
The sales figure stood at Rs. 26687.60 millions for the September 2023 quarter. The mentioned figure indicates a growth of about 36.99% as compared to Rs. 19482.10 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 105.98% to Rs. 3796.50  millions  from Rs. 1843.10 millions in previous same quarter.Operating Profit saw a handsome growth to 6122.60 millions from 3236.80 millions in the quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 26687.60 19482.10 36.99 50595.80 36898.60 37.12 127922.80 112871.40 13.33
Other Income 670.80 554.30 21.02 1619.60 933.10 73.57 4337.60 6709.90 -35.36
PBIDT 6122.60 3236.80 89.16 11295.20 5738.00 96.85 21646.80 21443.90 0.95
Interest 366.90 124.50 194.70 682.80 175.40 289.28 1149.80 169.40 578.75
PBDT 5755.70 3112.30 84.93 10612.40 5562.60 90.78 20497.00 20527.40 -0.15
Depreciation 657.90 607.00 8.39 1254.20 1167.10 7.46 4353.50 4152.60 4.84
PBT 5097.80 2505.30 103.48 9358.20 4395.50 112.90 16143.50 16374.80 -1.41
TAX 1301.30 662.20 96.51 2381.70 1194.70 99.36 3839.40 1827.70 110.07
Deferred Tax -70.40 -33.90 107.67 -153.00 -133.80 14.35 -230.80 -1969.30 -88.28
PAT 3796.50 1843.10 105.98 6976.50 3200.80 117.96 12304.10 14547.10 -15.42
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 22.94 16.61 38.08 22.32 15.55 43.56 16.92 19.00 -10.93

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×